154 related articles for article (PubMed ID: 12843689)
1. Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy.
Dornbrook-Lavender KA; Pieper JA
Cardiovasc Drugs Ther; 2003 Jan; 17(1):75-82. PubMed ID: 12843689
[TBL] [Abstract][Full Text] [Related]
2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
3. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic study of statin therapy and cholesterol reduction.
Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
9. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
[TBL] [Abstract][Full Text] [Related]
10. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
11. LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.
Wei WQ; Li X; Feng Q; Kubo M; Kullo IJ; Peissig PL; Karlson EW; Jarvik GP; Lee MTM; Shang N; Larson EA; Edwards T; Shaffer CM; Mosley JD; Maeda S; Horikoshi M; Ritchie M; Williams MS; Larson EB; Crosslin DR; Bland HT; Pacheco JA; Rasmussen-Torvik LJ; Cronkite D; Hripcsak G; Cox NJ; Wilke RA; Stein CM; Rotter JI; Momozawa Y; Roden DM; Krauss RM; Denny JC
Circulation; 2018 Oct; 138(17):1839-1849. PubMed ID: 29703846
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
14. A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients.
Versmissen J; Oosterveer DM; Yazdanpanah M; Mulder M; Dehghan A; Defesche JC; Kastelein JJ; Sijbrands EJ
Eur Heart J; 2011 Feb; 32(4):469-75. PubMed ID: 20595220
[TBL] [Abstract][Full Text] [Related]
15. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy.
Schmitz G; Drobnik W
Clin Chem Lab Med; 2003 Apr; 41(4):581-9. PubMed ID: 12747606
[TBL] [Abstract][Full Text] [Related]
17. [Statins in primary prevention of coronary heart disease].
Paulweber B
Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of response to statins: where do we stand?
Maitland-van der Zee AH; Boerwinkle E
Curr Atheroscler Rep; 2005 May; 7(3):204-8. PubMed ID: 15811254
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
[TBL] [Abstract][Full Text] [Related]
20. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG; Paterson JR
QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
